- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04840186
EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden (EXCALIBUR3)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Colorectal cancer (CRC) is the second most frequent malignant disease in Norway (Cancer in Norway 2017). About 50% of the patients will have metastatic disease at the time of diagnosis or develop metastatic disease later on. Liver metastases are the most frequent presentation of metastatic disease. Liver resection is considered the only curative treatment option in CRC patients with liver metastases, however only about 20% of the patients are candidates for liver resection. The treatment option for the majority of the patients is palliative chemotherapy with a median overall survival from start of chemotherapy of about 2 years, and only 10-12 months from starting 2nd line chemotherapy.
While high-quality data (randomized trials) is wanting, it is generally accepted that the only curative treatment for colorectal liver metastases (CRLM) is surgery. Liver resections are generally well tolerated and safe 1, but some patients recur early and probably have no benefit from surgery, or even a net loss of quality-of-life (QoL). These are hard to identify beforehand, but patients with multiple tumours that progress on 1st line chemotherapy are at high risk of early recurrence following resection2, 3. These patients are in a grey zone: their metastases may be technically resectable, but the aggressive biology of their disease makes overall outcome of surgery highly uncertain. The decision to offer resection to some of these patients primarily results from want of better alternatives and from lack of sufficiently precise prognostication.
As resections are generally well tolerated and adequate prognostication is wanting, there is a tendency to offer resections to patients who have borderline resectable CRLM or who exhibit other non-favourable traits like large or multiple metastases, or progression on 1st line chemotherapy. Resections followed by early recurrence represent a net loss of quality-of-life and an unwanted expenditure for society. Exploring the optimal treatment modality for patients in this grey zone, i.e. with uncertain benefit from surgery, is important to provide optimal treatment for patients in a critical situation.
Palliative chemotherapy is in general the only treatment option for the vast majority of non-resectable patients. The expected median overall survival (OS) from start of first line chemotherapy is about 2 years and the 5 years OS is about 10%, although longer median OS has been obtained in selected patients with good performance status (ECOG 0-1), no (K)RAS or BRAF mutations and left-sided tumours 4-8. The OS from start of second line chemotherapy however is only 10-12 months 9. This places the prognosis for this group of cancer patients on par with those having pancreatic cancer.
This trial targets a group of patients that are not eligible for the Excalibur 1 and 2 trials but still have as dismal or even worse prognosis. They will - according to the inclusion criteria - have a large tumour burden and have shown progression on 1st line systemic chemotherapy treatment. Based on previous trials, only 30 % of this patient group are estimated to be alive after two years. These patients have today only one treatment modality available: 2nd line systemic chemotherapy. Response can, however, only be expected in a small minority.
With such a dismal outcome for these patients, almost any attempt to improve survival would be warranted and anecdotal evidence shows that some appear to benefit substantially. This may, however, be a result of biased selection and the benefit of surgery in this grey zone is unproven.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: John Christian F Glent, MD
- Phone Number: 0047 92214992
- Email: uxgloh@ous-hf.no
Study Locations
-
-
-
Oslo, Norway, 0372
- Recruiting
- Oslo University Hospital
-
Contact:
- Victoria L Bringsjord, RN
- Phone Number: 0047 23073303
- Email: vicbri@ous-hf.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Verified adenocarcinoma in colon or rectum
Liver metastases that are technically resectable (ablation can be used as an adjunct) without PVE, HVE or ALPPS, but judged in need of further (next line) chemotherapy based on insufficient response to at least one line of chemotherapy. And either
a. Six or more liver metastases, with extra-hepatic disease i. def: >3 pulmonary metastases/radiologically positive non-liver hilar lymph nodes. Or b. Ten or more liver metastases with at least one of the following negative prognostic signs: i. At least one lesion > 7 cm in diameter before chemotherapy ii. CEA > 100 following a full cycle of chemotherapy)?? iii. KRAS and/or BRAF mutant primary tumour. iv. Node positive primary tumour. Or c. Fifteen or more liver metastases
- ECOG 0/2
- Informed consent
Exclusion Criteria:
Any of the following criteria will exclude participation in the trial:
New liver metastases emerging during completed chemotherapy.
a. These patients may be included if they undergo a complete cycle of next line chemotherapy without new liver metastases emerging.
- Previous or current bone or CNS metastatic disease
Any other reason why, in the opinion of the investigators, the patient should not participate.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 2nd line chhemotherapy
Patients in this arm will be receiving the standard care which is 2nd line chemotherapy.
Type of chemotherapy determined by treating oncologist.
|
2nd line chemotherapy.
Type of chemotherapy is determined by treating oncologist
|
ACTIVE_COMPARATOR: 2nd line chemotherapy + resection
Patients in this arm will be treated with liver resection and/or ablation at Oslo University Hospital followed by adjuvant 2nd line chemotherapy.
Type of chemotherapy is determined by treating oncologist.
|
2nd line chemotherapy.
Type of chemotherapy is determined by treating oncologist
Liver-resection of colorectal liver metastasis.
Ablation can be used as adjunct to surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median overall survival
Time Frame: 2years
|
Primary endpoint is median survival after two years to see if the survival is different in the two groups.
|
2years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life
Time Frame: EQ-5D-5L will be obtained at inclusion, week 6,12,18,24,36,48,60,72,84,96,108.
|
Quality of life will analyzed by EuroQoL Group questionaire EQ-5D-5L
|
EQ-5D-5L will be obtained at inclusion, week 6,12,18,24,36,48,60,72,84,96,108.
|
Progression free survival PFS
Time Frame: From inclusion to sign of progresion, tentatively less than 14months.
|
Time from inclusion to sign of progression defined by the RECIST-criteria
|
From inclusion to sign of progresion, tentatively less than 14months.
|
Quality of life
Time Frame: EORTC QLQ-C30 will be obtained at inclusion, week 6,12,18,24,36,48,60,72,84,96,108.
|
Quality of life will be analyzed by EORTC QLQ-C30
|
EORTC QLQ-C30 will be obtained at inclusion, week 6,12,18,24,36,48,60,72,84,96,108.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kristoffer Lassen, MD PhD, Oslo University Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 167434
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on 2nd line chemotherapy
-
Peking University People's HospitalPeking University Shougang HospitalCompletedPrognosis | Clinical Response | Histopathological ResponseChina
-
Dissou AFFOLABILondon School of Hygiene and Tropical Medicine; World Health Organization; Institute... and other collaboratorsCompletedTuberculosis, Multidrug-ResistantBelgium, Benin, Cameroon, Congo, The Democratic Republic of the, Ethiopia, Guinea, Mali, Nigeria, Rwanda, Senegal
-
National Cancer Institute, NaplesActive, not recruiting
-
Shanghai Gynecologic Oncology GroupZhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Shanghai Zhongshan...Active, not recruitingFallopian Tube Carcinoma | Ovarian Epithelial Cancer Recurrent | Primary Peritoneal CarcinomaChina
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Hebei Tumor HospitalUnknown
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of
-
Regina Elena Cancer InstituteFondazione Policlinico Universitario Agostino Gemelli IRCCS; University of... and other collaboratorsActive, not recruitingGastric Cancer | DNA DamageItaly
-
Inonu UniversityNot yet recruiting
-
Boehringer IngelheimCompleted